Table 3.
Subgroup analysis of the prognostic value of elevated CRP.
| Survival analysis | No. of studies | I2 (%) | HR (95% CI) | P |
|---|---|---|---|---|
| OS | ||||
| Total | 5 | 0% | 1.92 (1.52–2.42) | P < 0.00001 |
| Treatment | ||||
| Surgery | 4 | 0% | 1.88 (1.48–2.40) | P < 0.00001 |
| Mixed | 1 | NA | 2.33 (1.08–5.00) | P = 0.03 |
| Stage | ||||
| Non-metastatic | 1 | NA | 1.59 (0.68–3.71) | P = 0.28 |
| Metastatic | 4 | 0% | 1.95 (1.53–2.48) | P < 0.00001 |
| Ethnicity | ||||
| Asian | 2 | 0% | 1.96 (1.11–3.46) | P = 0.02 |
| Caucasian | 3 | 0% | 1.91 (1.48–2.46) | P < 0.00001 |
| DSS | ||||
| Total | 7 | 84% | 2.06 (1.32–3.22) | P = 0.001 |
| Treatment | ||||
| Surgery | 5 | 0% | 2.57 (1.91–3.45) | P < 0.00001 |
| Mixed | 2 | 73% | 1.32 (0.83–2.10) | P = 0.24 |
| Stage | ||||
| Non-metastatic | 3 | 54% | 2.72 (1.57–4.69) | P = 0.0003 |
| Metastatic | 1 | NA | 1.10 (1.03–1.18) | P = 0.005 |
| Mixed | 3 | 0% | 2.08 (1.44–3.01) | P < 0.0001 |
| Ethnicity | ||||
| Asian | 2 | 77% | 1.68 (0.62–4.54) | P = 0.30 |
| Caucasian | 5 | 16% | 2.29 (1.76–2.97) | P < 0.00001 |
| DFS | ||||
| Total | 5 | 0% | 1.75 (1.38–2.23) | P < 0.00001 |
| Treatment | ||||
| Surgery | 4 | 0% | 1.68 (1.31–2.16) | P < 0.0001 |
| Mixed | 1 | NA | 2.78 (1.19–6.48) | P = 0.02 |
| Stage | ||||
| Non-metastatic | 3 | 0% | 2.09 (1.31–3.31) | P = 0.002 |
| Mixed | 2 | 0% | 1.64 (1.24–2.18) | P = 0.0006 |
| Ethnicity | ||||
| Asian | 2 | 2% | 2.01 (1.13–3.57) | P = 0.02 |
| Caucasian | 3 | 0% | 1.70 (1.30–2.22) | P < 0.0001 |
NA, not available.